#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lymphatic malformation Niemann-Pick disease Congenital megacolon Chronic lymphocytic leukaemia refractory Scedosporium infection Chronic graft versus host disease Cystic fibrosis Anal cancer recurrent Hypomagnesaemia Salivary gland cancer Oesophageal adenocarcinoma stage III Ocular lymphoma IgA nephropathy Cystic fibrosis lung Follicle centre lymphoma follicular grade I, II – III More trials…

    Learn about Rare Diseases

    Alport’s syndrome – Basic Information Haemophilia – Life with Disease Hairy cell leukaemia recurrent – Life with Disease Leiomyosarcoma recurrent – Treatment MELAS syndrome – Treatment Synovial sarcoma metastatic – Trials in Disease Soft tissue sarcoma – Treatment Mastocytosis – Life with Disease Hepatoblastoma – Life with Disease Epidermolysis bullosa – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ORX750 Galcanezumab Dcc-3116 Eculizumab Vepdegestrant FERUMOXTRAN-10 Omx-0407 Hydrocortisone Hemisuccinate Human Plasma Protein Adezunap LUTETIUM LU-177 Vinorelbine Tartrate Stro-002 Alanine Tiratricol Tildrakizumab Vincristine Sulfate OXYBUTYNIN HYDROCHLORIDE Erdafitinib ANUMIGILIMAB More therapies…

    Learn about Your Condition

    Hyperchylomicronaemia Glomerulonephritis Testis cancer Sarcoidosis Pigmentary glaucoma Relapsing multiple sclerosis Osteoporosis postmenopausal Retinitis pigmentosa Endometriosis Hyperthyroidism Adenocarcinoma pancreas Univentricular heart Respiratory tract infection Scoliosis Subdural haematoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study of Plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

    Recruiting

    3 1
    Investigated Drugs:
    • Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
    Austria Belgium Bulgaria Croatia Czechia Hungary +6

  • Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Infliximab
    • Mycophenolate Mofetil
    • Rilvegostomig
    France Germany Italy The Netherlands Poland Spain

  • Study of empagliflozin compared to placebo in patients with acute decompensated heart failure who are already taking SGLT2 inhibitors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiac failure acute
    Investigated Drugs:
    • Empagliflozin
    Germany

  • Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • CEFTAROLINE FOSAMIL
    • Daptomycin
    • Levofloxacin
    France

  • Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Docetaxel
    Belgium France Germany Ireland Italy The Netherlands +2
Previous Page
1 … 157 158 159 160 161 … 1,648
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!